EMA Authorised: Tivdak (tisotumab vedotin) — Genmab A/S

View source ↗

Summary

The European Medicines Agency authorised Tivdak (tisotumab vedotin) for uterine cervical neoplasms, with Genmab A/S as the marketing authorization holder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Uterine Cervical Neoplasms

Drugs mentioned

• TIVDAK (tisotumab vedotin)

Snippet

Status: Authorised. Therapeutic area: Uterine Cervical Neoplasms. MAH: Genmab A/S. Decision date: 23/02/2026